AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2623126 — intervention group
Group type: COMPARATOR
Intervention: Heartbeat condition
Number of subjects: 114
Study 320828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine 70 mg t.i.d.
Number of subjects: 0
Study 320828 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 50 mg t.i.d.
Number of subjects: 0
Study 31411126 — intervention group
Group type: EXPERIMENTAL
Intervention: α-ketoglutaric acid (α-KG) and 5-hydroxymethylfurfural (5-HMF) supplementation
Number of subjects: 8
Study 31411126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29410318 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% diacerein cream
Number of subjects: 17
Study 29410318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 27089521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 356
Study 27089521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 25472724 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drinks (Nutricia pre‐Op) given the night before and the morning of surgery
Number of subjects: 30
Study 25472724 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks of equal volume
Number of subjects: 30
Study 25472724 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drinks (Nutricia pre‐Op)
Number of subjects: 30
Study 22915447 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Number of subjects: 550
Study 22915447 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 550
Study 22915447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 20335632 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplement (daily dose containing vitamins A, B complex, C, D, E, folic acid, copper, iron, and zinc)
Number of subjects: 118
Study 20335632 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplement
Number of subjects: 118
Study 20335632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 18242753 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (pelvic muscle exercises plus advice on healthy living)
Number of subjects: 47
Study 16170249 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight support treadmill training (BWSTT)
Number of subjects: 20
Study 16170249 — intervention group
Group type: COMPARATOR
Intervention: Conventional overground gait training (COGT)
Number of subjects: 20
Study 12525522 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 FEC 50
Number of subjects: 621
Study 12525522 — intervention group
Group type: COMPARATOR
Intervention: 3 FEC 50
Number of subjects: 621
Study 12525522 — intervention group
Group type: COMPARATOR
Intervention: 3 FEC 75
Number of subjects: 621
Study 10828560 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma irradiation (192Ir, 15 Gy at 2 mm from the source)
Number of subjects: 104
Study 10828560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 8953680 — intervention group
Group type: EXPERIMENTAL
Intervention: ornidazole 40 mg/kg as a single dose
Number of subjects: 48
Study 8953680 — intervention group
Group type: EXPERIMENTAL
Intervention: metronidazole 15 mg/kg as one dose for 7 days
Number of subjects: 48
Study 8953680 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole 100 mg t.i.d. for 7 days
Number of subjects: 48
Study 8953680 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole 100 mg t.i.d. for 1 day
Number of subjects: 48
Study 1801385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometry (test group)
Number of subjects: 3166
Study 1801385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tympanometry)
Number of subjects: 3166
Study 7290862 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training with trainer present
Number of subjects: 10
Study 7290862 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training with trainer absent
Number of subjects: 10
Study 7290862 — intervention group
Group type: COMPARATOR
Intervention: Information/placebo control with trainer present
Number of subjects: 10
Study 29703118 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone (model II)
Number of subjects: 816
Study 29703118 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) * total testosterone (model III)
Number of subjects: 816
Study 29703118 — intervention group
Group type: COMPARATOR
Intervention: Framingham Risk Score (FRS) variables (model I)
Number of subjects: 816
Study 29703118 — intervention group
Group type: COMPARATOR
Intervention: Model I
Number of subjects: 816
Study 29703118 — intervention group
Group type: EXPERIMENTAL
Intervention: Model II
Number of subjects: 816
Study 29703118 — intervention group
Group type: EXPERIMENTAL
Intervention: Model III
Number of subjects: 816
Study 29389568 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of pearl powder/d (n=10)
Number of subjects: 20
Study 29389568 — intervention group
Group type: COMPARATOR
Intervention: 3 g of placebo/d (n=10)
Number of subjects: 20
Study 26364892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SOPT) - 10 initial hours on-site
Number of subjects: 681
Study 26364892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SOPT) - 10 initial hours on-site plus 4 hours of boosters
Number of subjects: 681
Study 26364892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SOPT) - 10 initial hours at-home
Number of subjects: 681
Study 26364892 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group - 10 initial hours on-site of crossword puzzles
Number of subjects: 681
Study 24872573 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical vestibular stimulation with feet together
Number of subjects: 0
Study 24872573 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical vestibular stimulation with increased stance width
Number of subjects: 0
Study 24872573 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral light touch to produce anisotropy in stability
Number of subjects: 0
Study 22735277 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-units of Botox® (n = 7)
Number of subjects: 17
Study 22735277 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-units of Botox® (n = 5)
Number of subjects: 17
Study 22735277 — intervention group
Group type: COMPARATOR
Intervention: Saline (n = 5)
Number of subjects: 17
Study 19917841 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg
Number of subjects: 296
Study 19917841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 18622549 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS suite
Number of subjects: 16
Study 15757849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interstitial laser photocoagulation (ILP)
Number of subjects: 30
Study 15757849 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 30
Study 12443806 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 108
Study 12443806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 10852262 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE-specific risk adjustment index
Number of subjects: 4994
Study 10852262 — intervention group
Group type: COMPARATOR
Intervention: Charlson index
Number of subjects: 4994
Study 9735592 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme elbow flexion
Number of subjects: 20
Study 9735592 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviated wrist postures, forearm postures, and pinch type
Number of subjects: 20
Study 1845438 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0
Study 6179337 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure 2-3 times weekly for 4 weeks
Number of subjects: 0
Study 6179337 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA exposure 2-3 times weekly for 4 weeks
Number of subjects: 0
Study 6179337 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA exposure 2-3 times weekly for 4 weeks
Number of subjects: 0
Study 31515911 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal plane angulation of 2°
Number of subjects: 120
Study 31515911 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal plane cant
Number of subjects: 120
Study 28212320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with dairy foods
Number of subjects: 40
Study 28212320 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 40
Study 26483209 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile tea for 2 weeks
Number of subjects: 80
Study 26483209 — intervention group
Group type: COMPARATOR
Intervention: Regular postpartum care only (Control)
Number of subjects: 80
Study 24604768 — intervention group
Group type: EXPERIMENTAL
Intervention: Songs with pro-integration lyrics
Number of subjects: 0
Study 22147248 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination in IBD patients
Number of subjects: 102
Study 22147248 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccination in healthy controls
Number of subjects: 102
Study 20152225 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing with Closed Loop Stimulation (CLS)
Number of subjects: 108
Study 20152225 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing with accelerometer
Number of subjects: 108
Study 20152225 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 108
Study 17432680 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP) combined with sulfasalazine (SSZ)
Number of subjects: 67
Study 17432680 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) combined with sulfasalazine (SSZ)
Number of subjects: 67
Study 16123958 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed low-dose tacrolimus (target trough level 4-8 ng/mL, starting day 4-6) with daclizumab and mycophenolate mofetil
Number of subjects: 148
Study 16123958 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose tacrolimus with mycophenolate mofetil
Number of subjects: 148
Study 12069736 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin 150 microg nasal spray three times daily (Group B)
Number of subjects: 157
Study 12069736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin nasal spray 400 microg twice daily (Group N)
Number of subjects: 157
Study 12069736 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L)
Number of subjects: 157
Study 12069736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin group
Number of subjects: 157
Study 10195475 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (BL)
Number of subjects: 271
Study 10195475 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine (PL)
Number of subjects: 271
Study 8504631 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 6.5:93.5 non-protein nitrogen/protein nitrogen ratio
Number of subjects: 30
Study 8504631 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 11.4:88.6 non-protein nitrogen/protein nitrogen ratio
Number of subjects: 30
Study 8504631 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 17.5:82.5 non-protein nitrogen/protein nitrogen ratio
Number of subjects: 30
Study 8504631 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with higher proportion of non-protein nitrogen
Number of subjects: 30
Study 8504631 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 3304348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin sodium, 1 g intravenously, one hour prior to surgery and a similar dose eight hours later
Number of subjects: 101
Study 3304348 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 101
Study 29059293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded retainers (BRs)
Number of subjects: 60
Study 29059293 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-formed retainers (VFRs)
Number of subjects: 60
Study 27765759 — intervention group
Group type: EXPERIMENTAL
Intervention: Farglitazar
Number of subjects: 0
Study 27765759 — intervention group
Group type: EXPERIMENTAL
Intervention: Balaglitazone
Number of subjects: 0
Study 24670351 — intervention group
Group type: EXPERIMENTAL
Intervention: Krka's formulation of clopidogrel under fasting conditions
Number of subjects: 205
Study 24670351 — intervention group
Group type: EXPERIMENTAL
Intervention: Krka's formulation of clopidogrel under fed conditions
Number of subjects: 205
Study 24670351 — intervention group
Group type: COMPARATOR
Intervention: Innovator's formulation of clopidogrel under fasting conditions
Number of subjects: 205
Study 24670351 — intervention group
Group type: COMPARATOR
Intervention: Innovator's formulation of clopidogrel under fed conditions
Number of subjects: 205
Study 24670351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of clopidogrel
Number of subjects: 205
Study 23168362 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 3451
Study 23168362 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab-FOLFOX4
Number of subjects: 3451
Study 23168362 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab-XELOX
Number of subjects: 3451
Study 20360152 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised exercise programme
Number of subjects: 30
Study 20360152 — intervention group
Group type: COMPARATOR
Intervention: Self-supervised home exercise programme
Number of subjects: 30
Study 17316845 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 62
Study 17316845 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 62
Study 17316845 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Levosimendan vs Dobutamine
Number of subjects: 62
Study 16212577 — intervention group
Group type: EXPERIMENTAL
Intervention: 2(1/2) min. brushing
Number of subjects: 45
Study 16212577 — intervention group
Group type: COMPARATOR
Intervention: 2 min. brushing
Number of subjects: 45
Study 11951812 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release alpha-lipoic acid (CRLA) 900 mg daily for 6 weeks, then 1200 mg daily for an additional 6 weeks
Number of subjects: 21
Study 11951812 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release alpha-lipoic acid (CRLA)
Number of subjects: 21
Study 10402336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 1 mg/kg
Number of subjects: 30
Study 10402336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 1.5 mg/kg
Number of subjects: 30
Study 10402336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 2 mg/kg
Number of subjects: 30
Study 10402336 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 8918852 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention addressing AAS effects, sports nutrition, strength-training alternatives, drug refusal role play, anti-AAS media messages, and weight-room sessions.
Number of subjects: 1506
Study 8918852 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 1506
Study 1833800 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 42
Study 1833800 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 42
Study 1833800 — intervention group
Group type: EXPERIMENTAL
Intervention: xipamide
Number of subjects: 42
Study 6130151 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole
Number of subjects: 11
Study 6130151 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 11
Study 6130151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29595341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragi porridge supplementation for 90 days
Number of subjects: 60
Study 29595341 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ragi porridge)
Number of subjects: 60
Study 29595341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragi porridge supplementation
Number of subjects: 60
Study 29061598 — intervention group
Group type: EXPERIMENTAL
Intervention: Household conditional cash transfer programme (CCT)
Number of subjects: 6869
Study 25705007 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 261
Study 24265036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 22552025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle + limited variety (LV)
Number of subjects: 202
Study 22552025 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle
Number of subjects: 202
Study 19938957 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG and hCG
Number of subjects: 60
Study 17563129 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20mg plus remifentanil 0.3 microg/kg
Number of subjects: 129
Study 17563129 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 20mg
Number of subjects: 129
Study 17563129 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 0.3 microg/kg
Number of subjects: 129
Study 15062906 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education using a planned teaching method according to the patient education booklet
Number of subjects: 100
Study 15062906 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving information about pre‐ and postoperative routines from a nurse
Number of subjects: 100
Study 11475176 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% oxygen in nitrogen (2.5 L/min air with 0.5 L/min oxygen)
Number of subjects: 62
Study 11475176 — intervention group
Group type: COMPARATOR
Intervention: 33% oxygen in nitrous oxide (2 L/min nitrous oxide and 1 L/min oxygen)
Number of subjects: 62
Study 11475176 — intervention group
Group type: COMPARATOR
Intervention: Crying during induction
Number of subjects: 62
Study 9893601 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) for eubacterial genome
Number of subjects: 55
Study 9893601 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) for Propionibacterium acnes (P acnes)
Number of subjects: 55
Study 9893601 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-infective disorders)
Number of subjects: 55
Study 9893601 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of PCR in diagnosis
Number of subjects: 55
Study 9893601 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR on AH
Number of subjects: 55
Study 9609217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0
Study 9609217 — intervention group
Group type: COMPARATOR
Intervention: Adjusted dose heparin or warfarin
Number of subjects: 0
Study 2376845 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced 'harmful' anticipation
Number of subjects: 32
Study 2376845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer capacity test at 40 and 80 watt
Number of subjects: 32
Study 2376845 — intervention group
Group type: COMPARATOR
Intervention: Experimental variables (harmful vs non-harmful instructions)
Number of subjects: 32
Study 503385 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) gel (0.5 mg PGE2) intracervically
Number of subjects: 100
Study 503385 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin intravenously
Number of subjects: 100
Study 30985195 — intervention group
Group type: EXPERIMENTAL
Intervention: AMVCCT (Alberta Motor Vehicle Collision Culpability Tool)
Number of subjects: 175
Study 30985195 — intervention group
Group type: EXPERIMENTAL
Intervention: Culpable drivers (rated by AMVCCT)
Number of subjects: 175
Study 30985195 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-culpable drivers (rated by AMVCCT)
Number of subjects: 175
Study 30985195 — intervention group
Group type: EXPERIMENTAL
Intervention: Culpable drivers (gender comparison)
Number of subjects: 175
Study 30985195 — intervention group
Group type: EXPERIMENTAL
Intervention: Culpable drivers (alcohol impairment comparison)
Number of subjects: 175
Study 30985195 — intervention group
Group type: EXPERIMENTAL
Intervention: Culpable drivers (age comparison)
Number of subjects: 175
Study 30985195 — intervention group
Group type: EXPERIMENTAL
Intervention: Culpable drivers (time of day comparison)
Number of subjects: 175
Study 27671974 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg once daily
Number of subjects: 0
Study 27671974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25981818 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily
Number of subjects: 204
Study 25981818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 23252716 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioguanine
Number of subjects: 1150
Study 23252716 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Number of subjects: 1150
Study 23252716 — intervention group
Group type: COMPARATOR
Intervention: TPMT activity at diagnosis
Number of subjects: 1150
Study 23252716 — intervention group
Group type: COMPARATOR
Intervention: TPMT genotype-phenotype concordance
Number of subjects: 1150
Study 23252716 — intervention group
Group type: COMPARATOR
Intervention: TPMT intermediate activity patients with wild-type genotype
Number of subjects: 1150
Study 21129895 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberdeen Varicose Vein Questionnaire (AVVQ)
Number of subjects: 0
Study 21129895 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional, clinical, and hemodynamic measurements
Number of subjects: 0
Study 21129895 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific quality-of-life measures (AVVQ and SQOR-V)
Number of subjects: 0
Study 21129895 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical and hemodynamic measurements
Number of subjects: 0
Study 20108194 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral Buckling (SBS)
Number of subjects: 681
Study 20108194 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Vitrectomy (PV)
Number of subjects: 681